With more than 30 on­col­o­gy part­ners, Gilead lays out its 2030 vi­sion of 20 new ap­provals

Gilead has had a rocky his­to­ry in on­col­o­gy.

A brief re­count of the past few quar­ters: Trodelvy, the crown jew­el of Gilead’s $21 bil­lion Im­munomedics deal, un­der­whelmed Wall Street last month af­ter the com­pa­ny kept de­tails on the drug’s treat­ment of HR+/HER2- breast can­cer most­ly un­der wraps. There’s al­so the par­tial holds, some of which were re­cent­ly lift­ed, on the “break­through” ma­grolimab from the $4.9 bil­lion Forty Sev­en pur­chase. The CD47 drug had al­ready been through hur­dles with de­layed da­ta read­outs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER